| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 38.25 | 316.7% |
| Total Income | 38.25 | 316.7% |
| Expenditure | 69.54 | 17.9% |
| PBT | -26.09 | 44.4% |
| Net Profit | -26.09 | 44.4% |
| OPM | -81.83% | |
| NPM | -68.21% | |
| EPS | -0.13 | 55.2% |
Wave Life Sciences Reports Q1 2026 Financial Results and Business Update
28 Apr 2026 · 28 Apr, 5:11 pm
Summary
Wave Life Sciences Ltd. announced its first quarter 2026 financial results, reporting revenue of $38.2 million, a substantial increase from $9.2 million in the prior year quarter. The company recorded a net loss of $26.1 million for the quarter, while maintaining a robust cash position of $544.6 million, which is expected to fund operations into the third quarter of 2028. Management highlighted significant progress across its clinical pipeline, including the FDA's acceptance of the Phase 2a INLIGHT trial for WVE-007 and upcoming data presentations for WVE-006, underscoring a positive outlook for its RNA medicines.
Key Highlights
- 1
Wave Life Sciences reported a significant increase in revenue, reaching $38.2 million for the first quarter of 2026, compared to $9.2 million in the prior year quarter.
- 2
The company maintained a strong financial position with cash and cash equivalents totaling $544.6 million as of March 31, 2026, providing an expected cash runway into the third quarter of 2028.
- 3
Research and development expenses increased to $47.4 million in Q1 2026, up from $40.6 million in the same period of 2025, reflecting ongoing pipeline investment.
- 4
General and administrative expenses rose to $22.1 million for the first quarter of 2026, compared to $18.4 million in the prior year quarter.
- 5
The FDA accepted the Phase 2a multidose portion of the INLIGHT trial for WVE-007, with initiation on track for the second quarter of 2026.
- 6
Clinical data from the RestorAATion-2 trial of WVE-006 is expected to be presented at an investor webcast in May 2026, with regulatory feedback on accelerated approval anticipated mid-2026.
- 7
The company remains on track to file a New Drug Application (NDA) in 2026 for WVE-N531 to support accelerated approval with monthly dosing.
Management Comments
Paul Bolno
We’re accelerating WVE-007 to the next stages of development following the improvements in body composition already observed in the Phase 1 portion of our INLIGHT trial, including profound reductions in harmful visceral fat, along with favorable safety and potential for once to twice yearly dosing. This quarter, we expect to initiate the Phase 2a portion of INLIGHT in individuals with higher BMI and excess fat. Given WVE-007’s mechanism of targeted lipolysis, we believe this portion of the study can deliver even more pronounced improvements in body composition. Importantly, we’ve designed the Phase 2a study to assess additional biomarkers of cardiometabolic health, which will inform WVE-007’s broad potential across obesity and multiple indications, including MASH, type 2 diabetes, and cardiovascular disease. We also plan to rapidly initiate investigation of WVE-007 in both the combination and maintenance settings soon thereafter.
Paul Bolno
We continue to make significant progress advancing our RNA editing pipeline led by WVE-006 for AATD. Clinical data from our ongoing RestorAATion-2 trial of WVE-006 has already demonstrated the potential to provide a much-needed new therapeutic option. By correcting the root cause of disease, WVE-006 restores dynamic AAT production to address lung manifestations and lowers harmful Z-AAT to address liver manifestations of the disease, with a therapy that is well-tolerated, non-permanent, and highly specific. WVE-006 also avoids delivery with LNPs and collateral bystander edits and indels associated with DNA base editing. In May, we expect to highlight data from our RestorAATion-2 trial, including results from our less frequent, 400 mg monthly dose and 600 mg single dose cohorts. We remain on track to receive regulatory feedback on a potential accelerated approval pathway for WVE-006 mid-year. Building on our clinical success in RNAi and RNA editing, we are advancing WVE-008, as well as a pipeline of additional hepatic and extra-hepatic siRNAs and AIMers.
Informational and educational content only. Not investment advice.